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care environment, and data analytics. CONCLUSIONS: The integration of pharma-
cogenomic testingwith real-world studies offers an important opportunity to iden-
tify sub-groups of patients for whom treatment is more effective in terms of clin-
ical, and safety outcomes. Alongside resource utilization and cost of care data, this
evidence can be used to populate cost-effectiveness and other health economic
analyses to inform physician and payer decision-making.
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VALIDITY OF REQUIRING A MINIMUM DURATION OF POST-INDEX
ENROLLMENT IN RETROSPECTIVE DATABASE STUDIES
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OBJECTIVES: Retrospective database studies commonly use an inclusion criterion
requiring that subjects have a minimum duration of post-index enrollment (i.e.,
follow-up). Such a criterion can simplify analysis and facilitate computation of
annual costs. In clinical trials, however, similar strategies, such as analyses re-
stricted to subjects who completed follow-up (“complete case analysis”), are seen
as problematic because reasons for discontinuation may be related to study end-
points (i.e., informative censoring). METHODS: We reviewed methodologic litera-
ture and we used a health insurance claims database to evaluate the impact on
health care utilization and costs of excluding subjects lost to follow-up. RESULTS:
Excluding from analysis subjects with incomplete follow-up may be valid if pa-
tients aremissing at random. Unfortunately, this assumption can rarely be verified
because endpoints are usually unknown for patients who are lost to follow-up. In
an insurance claims database, an inclusion criterion requiring one year of fol-
low-up decreased health care utilization and average annual costs by 8% for a
random sample of subjects, and by 17% among subjects with a serious illness.
CONCLUSIONS: Subjects are lost to follow-up in both clinical trials and retrospec-
tive database studies (e.g., by exiting the database). Study populations should not
be defined in such a way as to exclude subjects lost to follow-up; instead, subjects
lost to follow-up should be considered as a missing data problem. In retrospective
database studies, just as in clinical trials, if endpoints among subjects lost to fol-
low-up differ from endpoints among subjects remaining in the database, restrict-
ing analysis to patientswithminimumdurations of follow-up candistort outcomes
and economic evaluations. Subjects lost to follow-up in automated databases
should be described and evaluated for evidence of informative censoring, and an-
alyzed using strategies appropriate for missing data, such as multiple imputation
methods.
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OBJECTIVES: To evaluate the potential for duplicate counting of prescriptionmed-
ication utilization for products that are billed through medical and prescription
claims. METHODS: A retrospective cross-sectional descriptive study was con-
ducted using the 2008 – 2011 Mississippi Medicaid data. Medical claims (MCs) with
J-codes for injectable medications were identified from MC files. Prescription
claims (PCs) for the corresponding beneficiaries were extracted from PC data for all
NDCs associated with the J-codes identified. These two sets of claims were stacked
to obtain a denominator file. Potential duplicate counts were identified by pairing
MCs and PCs for the same beneficiary and drug where the PC service date was
within 7 days of the MC service date. The Medicare maximum allowable cost was
identified for the J-code in each potential duplicate count situation. Criteria of the
MC being 80%of themaximumallowable cost for one J-code unit and theMC paid
amount being 80% of the corresponding PC paid amount were used to evaluate
which pairs might be actual duplicate counts. RESULTS: Out of 1,813,251 claims
identified in the denominator file, 1443 drug eventswere considered to be potential
duplicate counts (0.08%). These claims were associated with 849 Medicaid enroll-
ees. For 89%of the pairs, theMCpaid amountwas 80%of the allowable J-code unit
cost and 37% were 80% of the corresponding PC paid amount. Using a combina-
tion of these criteria, it was estimated that at least 47% of the pairs were likely to be
duplicate counts and that a large portion of the other pairs might be duplicate
counts. CONCLUSIONS: Researchers need to use caution when counting medica-
tion events for products reimbursed as MCs and PCs. The error from over-counting
at the population level should be small, but could have significant impact on utili-
zation and adherence estimates for individual patients.
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BACKGROUND: Numerous assumptions and techniques are associated with per-
forming meta-analysis. While some overall structural guidelines and recom-
mended practices exist, there are very few papers that compare meta-analysis
techniques in application.OBJECTIVES: To review primarymeta-analysismethods
and their assumptions, and apply various meta techniques to data and compare
the results. METHODS: There are currently a myriad of meta-analysis techniques
available. We started the study with a review of fixed effects models, which is the
most basic technique that assumes homogeneity in treatment effect across stud-
ies. We then explored random effect models and meta regression. Each of these
techniques models treatment heterogeneity. Other more advanced techniques ex-
amined included mixed treatment comparisons (MTC) and Bayesian approaches.
RESULTS: Estimates of treatment effect differed depending on themeta technique
applied. When a fixed effect model was applied to estimate the effect of a vaccina-
tion against tuberculosis, the log odds ratio was -0.436 (confidence interval [CI:
-0.528, -0.344]). After testing for heterogeneity and fitting a random effects model,
the estimate was reduced to -0.741 (CI [-1.12, -0.352]), and the CI became wider.
When covariates were added to the model to explain the heterogeneity, the treat-
ment effect was reduced even further. Additional techniques were applied as well,
such as BayesianMTC. CONCLUSIONS: Results frommeta-analysis are sensitive to
the studies selected, in addition to themethodology applied. To ensure that proper
techniques are used, it is critical to estimate an unbiased outcome.
RESEARCH ON METHODS – COST METHODS
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OBJECTIVES: Economic evaluations of drug therapy are important, but time con-
suming and costly. Analyses that are easily transferable (i.e. adjustable to a differ-
ent jurisdiction without completely rebuilding the model) may potentially save
time and resources. We aimed to develop a tool to assess and summarize the
general transferability ofmodel-based analyses.METHODS:Medline was searched
for literature on transferability published between 2002 and June 2011. Existing
checklists for economic evaluations were adapted to create a checklist of 16 key
factors to assess the general transferability of model-based analyses. This tool was
used to score 11 recently published economic evaluations and identify how well
specific factors were addressed. RESULTS: Transferability scores of the selected
papers ranged from 53–91%, illustrating the wide variability in the quality of re-
porting. Across all studies, the least well addressed transferability factors included
the discussion of the generalizability of the study results (lacking or incomplete in
all studies), adequate description of resources and costs employed in the analysis
(particularly separate reporting of resource use and unit costs), and adequate de-
scriptions of the method and/or populations used to derive utility values. The best
addressed transferability factors included those relating to country, currency and
discount rates. Even if studies scored highly overall, it may still be difficult to
transfer the findings to a different setting if they failed to report insufficient detail
on one or two key parameters. CONCLUSIONS: The general transferability of a
model-based economic evaluation from one country or jurisdiction to another can
be quickly assessed by the application of a simple checklist of key transferability
factors. It is important that authors ensure that they report their economic analysis
in a detailed and transparent fashion.
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OBJECTIVES: To perform a systematic literature review of pharmacoeconomic (PE)
publications considering recent United States (US) Food and Drug Administration
(FDA) new molecular entity and new biologic license approvals (NMEs/NBLs). The
review investigated publication quality and US relevance. METHODS: MEDLINE
and the United Kingdom National Health Service Economic Evaluation Database
were searched. Included publications considered 2008-2009 NMEs/NBLs in original
PE evaluations. In addition to general characteristics, each publication was evalu-
ated using the Quality of Health Economic Studies (QHES) Instrument. The corre-
lation between QHES scores and the 2010 Thomson Reuters five-year journal Im-
pact Factor (IF-5y) was calculated. Median QHES score differences were compared
(Mann-Whitney U) by study characteristics (yes/no): US context, academic first
author, pharmaceutical manufacturer funding (PMF), and declared author
independence. RESULTS: From 115 unique search results, 31met inclusion criteria.
Of fifty 2008-2009 NMEs/NBLs, 36% had PE publications, with 81% considering the
approval indication and 61% published post-approval. A US context was assessed
in 35% of publications. PMF was present in 68% of publications, comprising man-
ufacturers marketing either the NME/NBL, 90%, or a comparator, 10%. Time
(meanstandard deviation (S.D.)) since FDA approval was 21.98.8 months until
ePublication and 15.39.0 months until journal submission. Median and
meanS.D. QHES score were 78 and 73.316.4, respectively. Publications most
often satisfied QHES items regarding uncertainty (5) and incremental analysis (6)
(94% each). Justifiying the chosen model (13) and discussing biases (14) were satis-
fied least often (38% each). The IF-5y (mean 3.46, S.D. 3.37) was not correlated
with QHES score (Pearson r0.095, p0.636). QHES scores were not-significantly
different (p0.05) for any study characteristics. CONCLUSIONS: QHES scores indi-
cate PE studies of recent NMEs/NBLs are high quality, although US relevance is
imperfect: few publications assessed a US context; some did not consider the ap-
proval indication; publication lags delay PE evidence availability; and most publi-
cations have PMF.
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OBJECTIVES: To study whether theminimally important differences (MIDs) values
outcomes based on the behavioral economic theory. METHODS: We studied the
behavior of individuals discriminating minimally important differences (MIDs), a
method that identifies the change in a health measure necessary for a patient to
discriminate an improvement. The behavioral theory predicts that discrimination
of a quantity is governed byWeber’s Law: If a quantity is increased by some factor,
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the threshold for a MID also increases by this factor constantly. And this leads to
logarithmic function for quantifying outcomes. We examined a logarithmic func-
tional form for MIDs in nine pairs, a combination of three health states extracted
from EuroQol-5D (State A (21222), B (21122), and C (22222)) and three survival du-
rations (10, 20, and 30 years). An online survey was conducted and 100 subjects
were recruited. . One-way repeated measure analysis of variance and one-way
within subjects analysis were applied. RESULTS: A total of 98 subjects completed
the survey. In State A, the normalized mean of 10, 20, and 30 years were 0.63, 0.61,
and 0.59, respectively. There were no significant difference in the means (p 
0.1102). For State B, the normalized means were 0.66, 0.68, and 0.66 for 10, 20, and
30 years, respectively, with no significant difference among three durations (p 
0.6496). Lastly, in State C, the normalized means for the starting years were 0.57,
0.55, and 0.57, respectively, and there was no statistical difference (p  0.5404).
Thus, the impact of changing durations was not significant in all three states.
CONCLUSIONS: Our findings implies that the MID is constant over proportional
change in duration, indicating that the utility function of the MID follows a loga-
rithmic function. This violation of the normative decisionmodel implies treatment
decisions based on the MID may not represent our preferences for health.
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OBJECTIVES: Budget impact analyses (BIA) are important tools for assessing finan-
cial costs associated with the implementation of health care interventions. As
pressure on the limited budgets of health care systems increases, the role of BIA in
the reimbursement decision-making process is set to rise. Indeed, evidence sug-
gests that in recent years BIA conducted for new healthcare interventions have
increasingly informed reimbursement decisions of payers. The aim of this study
was to investigate any temporal and regional trends in the rate of study publica-
tions reporting the results of a BIA over the last ten years. METHODS: PubMed
searches were performed to identify publications discussing the budget impact of
treatments published for the years 2001, 2005, 2006 and 2010. For each year, the
number of publications including a BIA was calculated as a proportion of all pub-
lications for that year. The search findingswere examined to determine if temporal
or regional trends could be observed in the publication frequency of studies report-
ing BIA. RESULTS: From 2001 to 2005, a 3.7-fold increase was observed in the
proportion of the literature discussing BIA and from 2006 to 2010, a 3.5-fold in-
crease was observed. When the increasing temporal trend of BIA publication was
examined according to region (limited to Europe and the United States), it was
noted that the trend of an increase in the rate of BIA publication was greater in
Europe than in the USA. CONCLUSIONS: The period of 2001 – 2011 saw an increase
in the number of publications discussing BIA. This trend was more pronounced in
Europe than the US and likely reflects the funding differences of healthcare sys-
tems in these regions, with more limited healthcare budgets typical within Europe
compared to the United States. Future changes to the US health care system, how-
ever, may promote the increased use of BIA in this region.
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OBJECTIVES: To compare two different approaches to estimate the total cost Bo-
livia’s Expanded Program on Immunization (EPI), one using the central budget
reports vs. an alternative approach using a novel ProVac EPI costing Tool.
METHODS: The first approach was applied using cost data from the 2009 budget
approved to the Bolivian Ministry of Heath and regional sources of wage assign-
ments. We estimated the annual cost of Bolivian national EPI following the WHO
recommendations for estimating cost of immunization programs. The second ap-
proach use a new EPI costing tool developed by the PAHO ProVac Initiative and
designed to estimate the costs of every single component of a standard vaccination
program at three administrative levels (district, state, national). A costing survey
was carried out at different vaccination centers. RESULTS: The central level bud-
geting approach resulted in an overall EPI cost of US $11,960,000 for 2009. Using the
EPI costing tool to assess the local and regional costs of vaccination produced an
estimate four times higher, US $53,330,000. The most important items were the
purchase of vaccines and vaccination supplies (46% of the total), followed by per-
sonnelwho contributed about 28%. Cost incurred in the direct delivery of vaccine to
patients were 50% of the total, withmajor participation of personnel and transpor-
tation items. Other cost like vaccination supplies were best defined with this new
approach and also explains the incremental difference. CONCLUSIONS: The cen-
tral Budget cannot be relied on for a full estimation of EPI program costs, it can lose
cost details within the same level. Also, the costs incurred at lower administrative
levels were not well-captured in the central budget and are important of total EPI
costs. The costs of vaccination other than vaccine acquisition and vaccination
supplies are very important and should be considered in cost analysis of vaccine
introduction.
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OBJECTIVES: The purpose of this study is to assess the quality and characteristics
of dossiers submitted to HIRA, focusing on sensitivity analysis. METHODS: Two
researchers independently reviewed the 34 dossiers submitted from January 2007
to Dec. 2009. To analyze how submissions handled uncertainty, we analyzed the
analysis type, assessment items, and ranges of uncertainty and so on. Their adher-
ence to current HIRA’s recommendation was assessed. RESULTS: Thirty out of 34
dossiers performed sensitivity analysis. Deterministic sensitivity analysis, namely,
univariate analysis was most frequently used; probabilistic sensitivity analysis
(PSA) method was applied for only 5 cases and the grounds of the selection of
parameter distributions were rarely provided; 14 cases have provided the grounds
the ranges of uncertainty; 23 cases analyzed utility and effectiveness and 20 cases
analyzed drug cost for assessing uncertainty. Multivariate or threshold analyses
were rarely preformed. CONCLUSIONS: The quality of submitted dossiers in terms
of sensitivity analysis varied greatly. Revised HIRA’s guideline could specify the
minimum standards to reduce variability and increase the comparability of sub-
mitted dossiers.
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OBJECTIVES: The memory-less feature of Markov models can be a limiting factor
when treatment-sequencing needs to be modeled and the transition probability in
second- and subsequent-line treatments are not constant. Tunnel-states are a
common approach to overcome this limitation in cohort models built in excel. As
the number of treatment sequences and time-dependencies increase, however,
tunnel-states can become unruly. We propose an alternative method of nested
Markov modeling to allow time-dependency in treatment sequences. METHODS:
The proposed method first disaggregates the model by treatment and calculates
the costs and benefits for each treatment in the sequence. This effectively gives a
model of each treatment, which can be rolled back in the usual way to give a net
present value (NPV) of the costs and benefits after discounting. The NPVs of each
treatment are then combined into the treatment sequence by weighting propor-
tional to the time spent in the sequence, followed by further discounting to account
for placement in the sequence. This method is tested by building a hypothetical
model with two treatment sequences. i.e. first-line therapy and second-line ther-
apy, followed by a standard-of-care therapy as an absorbing state. Time depen-
dency was modelled by 1) the traditional tunnel state approach, and 2) the pro-
posed nested Markov model approach. RESULTS: Costs and quality-adjusted life-
years gained (discounted to NPV) were $456 and 2.87 for first-line therapy, $915 and
3.34 for second-line and standard-of-care therapy. The two approaches gave iden-
tical NPVs for the treatment sequence of $1296 and 5.94 QALYs. CONCLUSIONS:
Nested Markov modeling represents a straightforward and intuitive approach to
modeling a fixed treatment sequence. It may not be suitable if the position in a
sequence is inter-changeable, and treatment effectiveness depends on the position
in a sequence (e.g. cancer therapies where disease progression impacts treatment
effectiveness).
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OBJECTIVES: To estimate the total costs of the Bolivian Expanded Program of Im-
munization (EPI) from the perspective of the central level of the health system and
to estimate the average cost per fully immunized children (FIC) in the current
Bolivian setting.METHODS:Using cost data from the 2007-2009 budget approved to
the Bolivian MoH (Ministerio de la Salud y el Deporte) and regional sources of wage
assignments, we estimated the annual cost of Bolivian national EPI following the
WHO recommendations for estimating cost of immunization programs. Combin-
ing figures from EPI coverage and costs, cost per FIC were estimated with adjust-
ments for underreporting using secondary data sources. Costs are expressed in
2009 U.S. dollars. RESULTS: In 2007, 2008, and 2009 the Bolivian EPI central level
expended US$11,616,108, US$10,297,322, and US$11,959,509, respectively. The
most important items were vaccines purchasing and acquisition of vaccination
supplies (85% in average for 3 years), followed by personnel who contributed about
8,9% in average to same period. The cost per FIC was between US$ 6 and $93 with
basic scheme, and between $53 and $144 per FIC with basic scheme plus rotavirus.
CONCLUSIONS: This is one of the few studies in LAC attempting to establish the
cost of every single national EPI activity. The cost per child vaccinated in Bolivia is
explainedmainly by the costs of vaccines and personnel costs, however this result
should be considered as a very conservative one due to lack of cost data of inferior
levels of national EPI.
A161V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
